Abstract
Claudins are a superfamily of transmembrane proteins, the optimal expression and localization of which are important for the normal physiological function of the epithelium and any imbalance may have pathological consequences. Not only insufficient but also excessive production of claudins in cancer cells, as well as their aberrant localization, equally manifest the formation of a malignant phenotype. Many works are distinguished by contradictory data, which demonstrate the action of the same claudins both in the role of tumor-growth suppressors and promoters in the same cancers. The most important possible causes of significant discrepancies in the results of the works are a considerable variability of sampling and the absence of a consistent approach both to the assessment of the immune reactivity of claudins and to the differential analysis of their subcellular localization. Combined, these drawbacks hinder the histological assessment of the link between claudins and tumor progression. In particular, ambiguous expression of claudins in breast cancer subtypes, revealed by various authors in immunohistochemical analysis, not only fails to facilitate the identification of the claudin-low molecular subtype but rather complicates these efforts. Research into the role of claudins in carcinogenesis has undoubtedly confirmed the potential value of this class of proteins as significant biomarkers in some cancer types; however, the immunohistochemical approach to the assessment of claudins still has limitations, needs standardization, and, to date, has not reached a diagnostic or a prognostic value.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
Not applicable.
Code availability
Not applicable.
References
Amasheh S, Meiri N, Gitter AH, Schöneberg T, Mankertz J, Schulzke JD, Fromm M (2002) Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci 115:4969–4976. https://doi.org/10.1242/jcs.00165
Anderson JM, Van Itallie CM (2009) Physiology and function of the tight junction. Cold Spring Harb Perspect Biol 1:2584–2585. https://doi.org/10.1101/cshperspect.a002584
Angelow S, Schneeberger EE, Yu ASL (2007) Claudin-8 expression in renal epithelial cells augments the paracellular barrier by replacing endogenous claudin-2. J Membr Biol 215:147–159. https://doi.org/10.1007/s00232-007-9014-3
Angelow S, Ahlstrom R, Yu ASL (2008) Biology of claudins. Am J Physiol Ren Physiol 295:F867. https://doi.org/10.1152/ajprenal.90264.2008
Balda MS, Matter K (2008) Tight junctions at a glance. J Cell Sci 121:3677–3682. https://doi.org/10.1242/jcs.023887
Ben-Yosef T, Belyantseva IA, Saunders TL et al (2003) Claudin 14 knockout mice, a model for autosomal recessive deafness DFNB29, are deaf due to cochlear hair cell degeneration. Hum Mol Genet 12:2049–2061. https://doi.org/10.1093/hmg/ddg210
Bernardi MA, Logullo AF, Pasini FS, Nonogaki S, Blumke C, Soares FA, Brentani MM (2012) Prognostic significance of CD24 and claudin-7 immunoexpression in ductal invasive breast cancer. Oncol Rep 27:28–38. https://doi.org/10.3892/or.2011.1477
Berndt P, Winkler L, Cording J et al (2019) Tight junction proteins at the blood–brain barrier: far more than claudin-5. Cell Mol Life Sci 76:1987–2002. https://doi.org/10.1007/s00018-019-03030-7
Bhat AA, Pope JL, Smith JJ, Ahmad R, Chen X, Washington MK, Beauchamp RD, Singh AB, Dhawan P (2015) Claudin-7 expression induces mesenchymal to epithelial transformation (MET) to inhibit colon tumorigenesis. Oncogene 34:4570–4580. https://doi.org/10.1038/onc.2014.385
Bhat AA, Uppada S, Achkar IW, Hashem S, Yadav SK, Shanmugakonar M, Al-Naemi HA, Haris M, Uddin S (2019) Tight junction proteins and signaling pathways in cancer and inflammation: a functional crosstalk. Front Physiol 9:1942. https://doi.org/10.3389/fphys.2018.01942
Bhat AA, Syed N, Therachiyil L et al (2020) Claudin-1, a double-edged sword in cancer. Int J Mol Sci 21:569. https://doi.org/10.3390/ijms21020569
Blanchard AA, Skliris GP, Watson PH, Murphy LC, Penner C, Tomes L, Young TL, Leygue E, Myal Y (2009) Claudins 1, 3, and 4 protein expression in ER negative breast cancer correlates with markers of the basal phenotype. Virchows Arch 454:647–656. https://doi.org/10.1007/s00428-009-0770-6
Blanchard AA, Ma X, Dueck KJ, Penner C, Cooper SC, Mulhall D, Murphy LC, Leygue E, Myal Y (2013) Claudin 1 expression in basal-like breast cancer is related to patient age. BMC Cancer 13:268. https://doi.org/10.1186/1471-2407-13-268
Cadore E, Graudenz MS, Ferreira BP, Schulz R, Borba C, Uchoa D, Wagner MB (2019) Claudins 1, 3, 4, 7 and 10-year survival in triple-negative breast tumors. Mastology 29:71–78. https://doi.org/10.29289/2594539420190000419
Cereijido M, Contreras RG, Shoshani L, Flores-Benitez D, Larre I (2008) Tight junction and polarity interaction in the transporting epithelial phenotype. Biochim Biophys Acta Biomembr 1778:770–793. https://doi.org/10.1016/j.bbamem.2007.09.001
Chao YC, Pan SH, Yang SC et al (2009) Claudin-1 is a metastasis suppressor and correlates with clinical outcome in lung adenocarcinoma. Am J Respir Crit Care Med 179:123–133. https://doi.org/10.1164/rccm.200803-456OC
Chen X, Zhao J, Li A, Gao P, Sun J, Song Y, Liu J, Chen P, Wang Z (2016) Clinicopathological significance of claudin 4 expression in gastric carcinoma: a systematic review and meta-analysis. Onco Targets Ther 9:3205–3212
Choi YL, Kim J, Kwon MJ et al (2007) Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 22:1185–1195. https://doi.org/10.14670/HH-22.1185
Choi J, Jung WH, Koo JS (2012) Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers. Histol Histopathol 27:1481–1493. https://doi.org/10.14670/HH-27.1481
Colegio OR, Van Itallie CM, McCrea HJ, Rahner C, Anderson JM (2002) Claudins create charge-selective channels in the paracellular pathway between epithelial cells. Am J Physiol Cell Physiol 283:C142–C147. https://doi.org/10.1152/ajpcell.00038.2002
Curtis C, Shah SP, Chin SF et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346–352. https://doi.org/10.1038/nature10983
Dahiya N, Becker KG, Wood WH, Zhang Y, Morin PJ (2011) Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion. PLoS ONE. https://doi.org/10.1371/journal.pone.0022119
De Oliveira SS, De Oliveira IM, De Souza W, Morgado-Díaz JA (2005) Claudins upregulation in human colorectal cancer. FEBS Lett 579:6179–6185. https://doi.org/10.1016/j.febslet.2005.09.091
Dhawan P, Singh AB, Deane NG, No YR, Shiou SR, Schmidt C, Neff J, Washington MK, Beauchamp RD (2005) Claudin-1 regulates cellular transformation and metastatic behavior in colon cancer. J Clin Invest 115:1765–1776. https://doi.org/10.1172/JCI24543
Dias K, Dvorkin-Gheva A, Hallett RM, Wu Y, Hassell J, Pond GR, Levine M, Whelan T, Bane AL (2017) Claudin-low breast cancer; clinical and pathological characteristics. PLoS ONE 12:e0168669. https://doi.org/10.1371/journal.pone.0168669
Du G, Gu Y, Hao C, Yuan Z, He J, Jiang WG, Cheng S (2016) The cellular distribution of Na+/H+ exchanger regulatory factor 1 is determined by the PDZ-I domain and regulates the malignant progression of breast cancer. Oncotarget 7:29440–29453. https://doi.org/10.18632/oncotarget.8751
Dukes JD, Fish L, Richardson JD, Blaikley E, Burns S, Caunt CJ, Chalmers AD, Whitley P (2011) Functional ESCRT machinery is required for constitutive recycling of claudin-1 and maintenance of polarity in vertebrate epithelial cells. Mol Biol Cell 22:3192–3205. https://doi.org/10.1091/mbc.E11-04-0343
Fougner C, Bergholtz H, Norum JH, Sørlie T (2020) Re-definition of claudin-low as a breast cancer phenotype. Nat Commun 11:1–11. https://doi.org/10.1038/s41467-020-15574-5
Furuse M, Hirase T, Itoh M, Nagafuchi A, Yonemura S, Tsukita S, Tsukita S (1993) Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 123:1777–1788. https://doi.org/10.1083/jcb.123.6.1777
Furuse M, Fujita K, Hiiragi T, Fujimoto K, Tsukita S (1998) Claudin-1 and -2: novel integral membrane proteins localizing at tight junctions with no sequence similarity to occludin. J Cell Biol 141:1539–1550. https://doi.org/10.1083/jcb.141.7.1539
Furuse M, Sasaki H, Tsukita S (1999) Manner of interaction of heterogeneous claudin species within and between tight junction strands. J Cell Biol 147:891–903. https://doi.org/10.1083/jcb.147.4.891
Furuse M, Hata M, Furuse K, Yoshida Y, Haratake A, Sugitani Y, Noda T, Kubo A, Tsukita S (2002) Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice. J Cell Biol 156:1099–1111. https://doi.org/10.1083/jcb.200110122
Gerhard R, Ricardo S, Albergaria A, Gomes M, Silva AR, Logullo ÂF, Cameselle-Teijeiro JF, Paredes J, Schmitt F (2012) Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast 21:354–360. https://doi.org/10.1016/j.breast.2012.03.001
González-Mariscal L, Tapia R, Chamorro D (2008) Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta Biomembr 1778:729–756. https://doi.org/10.1016/j.bbamem.2007.08.018
González-Mariscal L, Garay E, Quirós M (2010) Regulation of claudins by posttranslational modifications and cell-signaling cascades. Current topics in membranes. Academic Press, Cambridge, pp 113–150
Gottardi CJ, Arpin M, Fanning AS, Louvard D (1996) The junction-associated protein, zonula occludens-1, localizes to the nucleus before the maturation and during the remodeling of cell-cell contacts. Proc Natl Acad Sci U S A 93:10779–10784. https://doi.org/10.1073/pnas.93.20.10779
Hagen SJ (2017) Non-canonical functions of claudin proteins: beyond the regulation of cell-cell adhesions. Tissue Barriers 5:e1327839. https://doi.org/10.1080/21688370.2017.1327839
Hahn-Strömberg V, Askari S, Ahmad A, Befekadu R, Nilsson TK (2017) Expression of claudin 1, claudin 4, and claudin 7 in colorectal cancer and its relation with CLDN DNA methylation patterns. Tumor Biol 39:1010428317697569. https://doi.org/10.1177/1010428317697569
Hamazaki Y, Itoh M, Sasaki H, Furuse M, Tsukita S (2002) Multi-PDZ domain protein 1 (MUPP1) is concentrated at tight junctions through its possible interaction with claudin-1 and junctional adhesion molecule. J Biol Chem 277:455–461. https://doi.org/10.1074/jbc.M109005200
Heiler S, Mu W, Zöller M, Thuma F (2015) The importance of claudin-7 palmitoylation on membrane subdomain localization and metastasis-promoting activities. Cell Commun Signal 13:29. https://doi.org/10.1186/s12964-015-0105-y
Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K et al (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69:4116–4124. https://doi.org/10.1158/0008-5472.CAN-08-3441
Herschkowitz JI, Simin K, Weigman VJ et al (2007) Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 8:R76. https://doi.org/10.1186/gb-2007-8-5-r76
Hibbs K, Skubitz KM, Pambuccian SE et al (2004) Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165:397–414. https://doi.org/10.1016/S0002-9440(10)63306-8
Higashi Y, Suzuki S, Sakaguchi T, Nakamura T, Baba S, Reinecker HC, Nakamura S, Konno H (2007) Loss of claudin-1 expression correlates with malignancy of hepatocellular carcinoma. J Surg Res 139:68–76. https://doi.org/10.1016/j.jss.2006.08.038
Huang J, Li J, Qu Y, Zhang J, Zhang L, Chen X, Liu B, Zhu Z (2014) The expression of claudin 1 correlates with β-catenin and is a prognostic factor of poor outcome in gastric cancer. Int J Oncol 44:1293–1301. https://doi.org/10.3892/ijo.2014.2298
Huang J, Zhang L, He C, Qu Y, Li J, Zhang J, Du T, Chen X, Yu Y, Liu B, Zhu Z (2015) Claudin-1 enhances tumor proliferation and metastasis by regulating cell anoikis in gastric cancer. Oncotarget 6:1652–1665. https://doi.org/10.18632/oncotarget.2936
Huo Q, Kinugasa T, Wang L et al (2009) Claudin-1 protein is a major factor involved in the tumorigenesis of colorectal cancer. Anticancer Res 29:851–857
Hwang TL, Lee LY, Wang CC, Liang Y, Huang SF, Wu CM (2010) Claudin-4 expression is associated with tumor invasion, MMP-2 and MMP-9 expression in gastric cancer. Exp Ther Med 1:789–797. https://doi.org/10.3892/etm.2010.116
Ikari A, Watanabe R, Sato T et al (2014) Nuclear distribution of claudin-2 increases cell proliferation in human lung adenocarcinoma cells. Biochim Biophys Acta Mol Cell Res 1843:2079–2088. https://doi.org/10.1016/j.bbamcr.2014.05.017
Islas S, Vega J, Ponce L, González-Mariscal L (2002) Nuclear localization of the tight junction protein ZO-2 in epithelial cells. Exp Cell Res 274:138–148. https://doi.org/10.1006/excr.2001.5457
Itoh M, Furuse M, Morita K, Kubota K, Saitou M, Tsukita S (1999) Direct binding of three tight junction-associated MAGUKs, ZO-1, ZO-2, and ZO-3, with the COOH termini of claudins. J Cell Biol 147:1351–1363. https://doi.org/10.1083/jcb.147.6.1351
Jääskeläinen A, Soini Y, Jukkola-Vuorinen A, Auvinen P, Haapasaari KM, Karihtala P (2018) High-level cytoplasmic claudin 3 expression is an independent predictor of poor survival in triple-negative breast cancer. BMC Cancer 18:223. https://doi.org/10.1186/s12885-018-4141-z
Jakab C, Halász J, Szász AM, Batmunkh E, Kiss A, Schaff Z, Rusvai M, Gálfi P, Kulka J (2008) Expression and localisation of claudin-1, -2, -3, -4, -5, -7 and -10 proteins in the normal canine mammary gland. Acta Vet Hung 56:341–352. https://doi.org/10.1556/AVet.56.2008.3.8
Jia H, Chai X, Li S, Wu D, Fan Z (2019) Identification of claudin-2, -6, -11 and -14 as prognostic markers in human breast carcinoma. Int J Clin Exp Pathol 12:2195–2204
Jo VY, Cibas ES, Pinkus GS (2014) Claudin-4 immunohistochemistry is highly effective in distinguishing adenocarcinoma from malignant mesothelioma in effusion cytology. Cancer Cytopathol 122:299–306. https://doi.org/10.1002/cncy.21392
Kaf R, Saba E, Refaat W, Bahgat A (2016) The significance of claudin-1 and S100A4 expression in primary colorectal carcinoma. Zagazig Univ Med J 22:1–12
Kardos J, Chai S, Mose LE et al (2016) Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. JCI Insight 1:e85902. https://doi.org/10.1172/jci.insight.85902
Katayama A, Handa T, Komatsu K, Togo M, Horiguchi J, Nishiyama M, Oyama T (2017) Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome. Pathol Int 67:404–413. https://doi.org/10.1111/pin.12560
Kausalya PJ, Phua DCY, Hunziker W (2004) Association of ARVCF with zonula occludens (ZO)-1 and ZO-2: binding to PDZ-domain proteins and cell-cell adhesion regulate plasma membrane and nuclear localization of ARVCF. Mol Biol Cell 15:5503–5515. https://doi.org/10.1091/mbc.E04-04-0350
Kinugasa T, Huo Q, Higashi D et al (2007) Selective up-regulation of claudin-1 and claudin-2 in colorectal cancer. Anticancer Res 27:3729–3734
Kischel P, Bellahcene A, Deux B, Lamour V, Dobson R, Pauw DE, Clezardin P, Castronovo V (2012) Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. Anticancer Res 32:5211–5220
Kitajiri SI, Miyamoto T, Mineharu A et al (2004) Compartmentalization established by claudin-11-based tight junctions in stria vascularis is required for hearing through generation of endocochlear potential. J Cell Sci 117:5087–5096. https://doi.org/10.1242/jcs.01393
Koboldt DC, Fulton RS, McLellan MD et al (2012) Comprehensive molecular portraits of human breast tumours. Nature 490:61–70. https://doi.org/10.1038/nature11412
Kolokytha P, Yiannou P, Keramopoulos D, Kolokythas A, Nonni A, Patsouris E, Pavlakis K (2014) Claudin-3 and claudin-4: distinct prognostic significance in triple-negative and luminal breast cancer. Appl Immunohistochem Mol Morphol 22:125–131. https://doi.org/10.1097/PAI.0b013e31828d9d62
Kominsky SL, Argani P, Korz D et al (2003) Loss of the tight junction protein claudin-7 correlates with histological grade in both ductal carcinoma in situ and invasive ductal carcinoma of the breast. Oncogene 22:2021–2033. https://doi.org/10.1038/sj.onc.1206199
Koval M (2013) Claudin heterogeneity and control of lung tight junctions. Annu Rev Physiol 75:551–567. https://doi.org/10.1146/annurev-physiol-030212-183809
Kovalenko OV, Yang XH, Hemler ME (2007) A novel cysteine cross-linking method reveals a direct association between claudin-1 and tetraspanin CD9. Mol Cell Proteomics 6:1855–1867. https://doi.org/10.1074/mcp.M700183-MCP200
Kulka J, Szász AM, Németh Z, Madaras L, Schaff Z, Molnár IA, Tokés AM (2009) Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathol Oncol Res 15:59–64. https://doi.org/10.1007/s12253-008-9089-x
Kwon MJ (2013) Emerging roles of claudins in human cancer. Int J Mol Sci 14:18148–18180. https://doi.org/10.3390/ijms140918148
Lanigan F, McKiernan E, Brennan DJ et al (2009) Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 124:2088–2097. https://doi.org/10.1002/ijc.24159
Lee JW, Hsiao WT, Chen HY, Hsu LP, Chen PR, Der LM, Chiu SJ, Shih WL, Hsu YC (2010) Upregulated claudin-1 expression confers resistance to cell death of nasopharyngeal carcinoma cells. Int J Cancer 126:1353–1366. https://doi.org/10.1002/ijc.24857
Leech AO, Cruz RGB, Hill ADK, Hopkins AM (2015) Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis. Ann Transl Med 3:184–198. https://doi.org/10.3978/j.issn.2305-5839.2015.08.01
Liu W, Li M (2020) The role of claudin-4 in the development of gastric cancer. Scand J Gastroenterol 55:1072–1078
Logullo A, Pasini F, Nonogaki S, Rocha R, Soares F, Brentani M (2018) Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: a large diagnostic study using tissue microarray. Mol Clin Oncol 9:377–388. https://doi.org/10.3892/mco.2018.1685
Lu S, Singh K, Mangray S, Tavares R, Noble L, Resnick MB, Yakirevich E (2013) Claudin expression in high-grade invasive ductal carcinoma of the breast: correlation with the molecular subtype. Mod Pathol 26:485–495. https://doi.org/10.1038/modpathol.2012.187
Maetzel D, Denzel S, Mack B et al (2009) Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 11:162–171. https://doi.org/10.1038/ncb1824
Martin TA, Jiang WG (2009) Loss of tight junction barrier function and its role in cancer metastasis. Biochim Biophys Acta Biomembr 1788:872–891. https://doi.org/10.1016/j.bbamem.2008.11.005
Martin TA, Lane J, Ozupek H, Jiang WG (2013) Claudin-20 promotes an aggressive phenotype in human breast cancer cells. Tissue Barriers 1:e26518. https://doi.org/10.4161/tisb.26518
Mattissek C, Teis D (2014) The role of the endosomal sorting complexes required for transport (ESCRT) in tumorigenesis. Mol Membr Biol 31:111–119. https://doi.org/10.3109/09687688.2014.894210
Men W, Martin TA, Ruge F, Zhang N, Du P, Yang Y, Jiang WG (2015) Expression of claudins in human clear cell renal cell carcinoma. Cancer Genomics Proteomics 12:1–8
Mineta K, Yamamoto Y, Yamazaki Y et al (2011) Predicted expansion of the claudin multigene family. FEBS Lett 585:606–612. https://doi.org/10.1016/j.febslet.2011.01.028
Miyamoto T, Morita K, Takemoto D et al (2005) Tight junctions in Schwann cells of peripheral myelinated axons: a lesson from claudin-19-deficient mice. J Cell Biol 169:527–538. https://doi.org/10.1083/jcb.200501154
Miyamoto K, Kusumi T, Sato F, Kawasaki H, Shibata S, Ohashi M, Hakamada K, Sasaki M, Kijima H (2008) Decreased expression of claudin-1 is correlated with recurrence status in esophageal squamous cell carcinoma. Biomed Res 29:71–76. https://doi.org/10.2220/biomedres.29.71
Morita K, Furuse M, Fujimoto K, Tsukita S (1999) Claudin multigene family encoding four-transmembrane domain protein components of tight junction strands. Proc Natl Acad Sci U S A 96:511–516. https://doi.org/10.1073/pnas.96.2.511
Morohashi S, Kusumi T, Sato F, Odagiri H, Chiba H, Yoshihara S, Hakamada K, Sasaki M, Kijima H (2007) Decreased expression of claudin-1 correlates with recurrence status in breast cancer. Int J Mol Med 20:139–143. https://doi.org/10.3892/ijmm.20.2.139
Mrsny RJ, Brown GT, Gerner-Smidt K, Buret AG, Meddings JB, Quan C, Koval M, Nusrat A (2008) A key claudin extracellular loop domain is critical for epithelial barrier integrity. Am J Pathol 172:905–915. https://doi.org/10.2353/ajpath.2008.070698
Myal Y, Leygue E, Blanchard AA (2010) Claudin 1 in breast tumorigenesis: Revelation of a possible novel “claudin high” subset of breast cancers. J Biomed Biotechnol 2010:956897. https://doi.org/10.1155/2010/956897
Nishijima TF, Kardos J, Chai S et al (2017) Molecular and clinical characterization of a caudin-low subtype of gastric cancer. JCO Precis Oncol. https://doi.org/10.1200/po.17.00047
Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S (2003) Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol 161:653–660. https://doi.org/10.1083/jcb.200302070
Oku N, Sasabe E, Ueta E, Yamamoto T, Osaki T (2006) Tight junction protein claudin-1 enhances the invasive activity of oral squamous cell carcinoma cells by promoting cleavage of laminin-5 γ2 chain via matrix metalloproteinase (MMP)-2 and membrane-type MMP-1. Cancer Res 66:5251–5257. https://doi.org/10.1158/0008-5472.CAN-05-4478
Ono Y, Hiratsuka Y, Murata M et al (2016) Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma. Virchows Arch 469:417–426. https://doi.org/10.1007/s00428-016-1984-z
Osanai M, Takasawa A, Murata M, Sawada N (2017) Claudins in cancer: bench to bedside. Pflugers Arch Eur J Physiol 469:55–67. https://doi.org/10.1007/s00424-016-1877-7
Paskarani PE, Saputra H, Sriwidyani NP, Sri Mahendra Dewi IGA, Maker LPII, Muliartha IM (2020) Low claudin-1 expression has association with deep invading and higher-grade colorectal adenocarcinoma. Indones J Cancer 14:21. https://doi.org/10.33371/ijoc.v14i1.677
Pereira B, Chin SF, Rueda OM et al (2016) The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun 7:11479. https://doi.org/10.1038/ncomms11479
Perou CM, Sørlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752. https://doi.org/10.1038/35021093
Philip R, Heiler S, Mu W, Büchler MW, Zöller M, Thuma F (2015) Claudin-7 promotes the epithelial-mesenchymal transition in human colorectal cancer. Oncotarget 6:2046–2063. https://doi.org/10.18632/oncotarget.2858
Piorntek J, Winkler L, Wolburg H, Müller SL, Zuleger N, Piehl C, Wiesner B, Krause G, Blasig IE (2008) Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J 22:146–158. https://doi.org/10.1096/fj.07-8319com
Pope JL, Ahmad R, Bhat AA, Washington MK, Singh AB, Dhawan P (2014) Claudin-1 overexpression in intestinal epithelial cells enhances susceptibility to adenamatous polyposis coli-mediated colon tumorigenesis. Mol Cancer 13:167. https://doi.org/10.1186/1476-4598-13-167
Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5–23. https://doi.org/10.1016/j.molonc.2010.11.003
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68. https://doi.org/10.1186/bcr2635
Rahman A, Kobayashi M, Sugimoto K et al (2021) Reduced claudin-12 expression predicts poor prognosis in cervical cancer. Int J Mol Sci. https://doi.org/10.3390/ijms22073774
Rangel LBA, Agarwal R, D’Souza T et al (2003) Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9:2567–2575
Rendon-Huerta E, Chavarria-Velazquez C, Montaño L (2013) Claudins, inflammation and epithelial-mesenchymal transition in gastric tissue. J Gastrointest Dig Syst. https://doi.org/10.4172/2161-069x.1000149
Romani C, Zizioli V, Silvestri M et al (2020) Low expression of claudin-7 as potential predictor of distant metastases in high-grade serous ovarian carcinoma patients. Front Oncol. https://doi.org/10.3389/fonc.2020.01287
Romani C, Capoferri D, Grillo E et al (2021) The claudin-low subtype of high-grade serous ovarian carcinoma exhibits stem cell features. Cancers (basel) 13:1–18. https://doi.org/10.3390/cancers13040906
Rüffer C, Gerke V (2004) The C-terminal cytoplasmic tail of claudins 1 and 5 but not its PDZ-binding motif is required for apical localization at epithelial and endothelial tight junctions. Eur J Cell Biol 83:135–144. https://doi.org/10.1078/0171-9335-00366
Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F (2014) Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer 13:228. https://doi.org/10.1186/1476-4598-13-228
Sauer T, Pedersen MK, Ebeltoft K, Næss O (2005) Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease. Cytopathology 16:193–198. https://doi.org/10.1111/j.1365-2303.2005.00257.x
Schmidt O, Teis D (2012) The ESCRT machinery. Curr Biol 22:R116. https://doi.org/10.1016/j.cub.2012.01.028
Schnell U, Cirulli V, Giepmans BNG (2013) EpCAM: structure and function in health and disease. Biochim Biophys Acta Biomembr 1828:1989–2001. https://doi.org/10.1016/j.bbamem.2013.04.018
Seo KW, Kwon YK, Kim BH, Il KC, Chang HS, Choe MS, Park CH (2010) Correlation between claudins expression and prognostic factors in prostate cancer. Korean J Urol 51:239–244. https://doi.org/10.4111/kju.2010.51.4.239
Shareef MM, Radi DMA, Eid AMM (2015) Tight junction protein claudin 4 in gastric carcinoma and its relation to lymphangiogenic activity. Arab J Gastroenterol 16:105–112. https://doi.org/10.1016/j.ajg.2015.09.008
Sheehan GM, Kallakury BVS, Sheehan CE, Fisher HAG, Kaufman RP, Ross JS (2007) Loss of claudins-1 and -7 and expression of claudins-3 and -4 correlate with prognostic variables in prostatic adenocarcinomas. Hum Pathol 38:564–569. https://doi.org/10.1016/j.humpath.2006.11.007
Shen Z, Song W, Qian L, Zhu J, Li Y, Li M, Zhang T, Zhao W, Zhou Y, Yang X (2021) Effect of claudin 1 on cell proliferation, migration and apoptosis in human cervical squamous cell carcinoma. Oncol Rep 45:606–618. https://doi.org/10.3892/or.2020.7889
Singh AB, Sharma A, Smith JJ et al (2011) Claudin-1 up-regulates the repressor ZEB-1 to inhibit E-cadherin expression in colon cancer cells. Gastroenterology 141:2140–2153. https://doi.org/10.1053/j.gastro.2011.08.038
Sobel G, Németh J, Kiss A, Lotz G, Szabó I, Udvarhelyi N, Schaff Z, Páska C (2006) Claudin 1 differentiates endometrioid and serous papillary endometrial adenocarcinoma. Gynecol Oncol 103:591–598. https://doi.org/10.1016/j.ygyno.2006.04.005
Soini Y (2005) Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology 46:551–560. https://doi.org/10.1111/j.1365-2559.2005.02127.x
Soini Y, Kinnula V, Kahlos K, Pääkkö P (2006a) Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol 59:250–254. https://doi.org/10.1136/jcp.2005.028589
Soini Y, Tommola S, Helin H, Martikainen P (2006b) Claudins 1, 3, 4 and 5 in gastric carcinoma, loss of claudin expression associates with the diffuse subtype. Virchows Arch 448:52–58. https://doi.org/10.1007/s00428-005-0011-6
Sørlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874. https://doi.org/10.1073/pnas.191367098
Süren D, Yildirim M, Kaya V, Alikanoǧlu AS, Bülbüller N, Yildiz M, Sezer C (2014) Loss of tight junction proteins (Claudin 1, 4, and 7) correlates with aggressive behavior in colorectal carcinoma. Med Sci Monit 20:1255–1262. https://doi.org/10.12659/MSM.890598
Süren D, Yildirim M, Sayiner A et al (2017) Expression of claudin 1, 4 and 7 in thyroid neoplasms. Oncol Lett 13:3722–3726. https://doi.org/10.3892/ol.2017.5916
Suzuki K, Sentani K, Tanaka H, Yano T, Suzuki K, Oshima M, Yasui W, Tamura A, Tsukita S (2019) Deficiency of stomach-type claudin-18 in mice induces gastric tumor formation independent of H pylori infection. CMGH 8:119–142. https://doi.org/10.1016/j.jcmgh.2019.03.003
Szasz AM, Nemeth Z, Gyorffy B et al (2011) Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. Cancer Sci 102:2248–2254. https://doi.org/10.1111/j.1349-7006.2011.02085.x
Tabariès S, Siegel PM (2017) The role of claudins in cancer metastasis. Oncogene 36:1176–1190. https://doi.org/10.1038/onc.2016.289
Tanaka M, Kamata R, Sakai R (2005) Phosphorylation of ephrin-B1 via the interaction with claudin following cell-cell contact formation. EMBO J 24:3700–3711. https://doi.org/10.1038/sj.emboj.7600831
Tassi RA, Bignotti E, Falchetti M et al (2008) Claudin-7 expression in human epithelial ovarian cancer. Int J Gynecol Cancer 18:1262–1271. https://doi.org/10.1111/j.1525-1438.2008.01194.x
Thuma F, Heiler S, Schnölzer M, Zöller M (2016) Palmitoylated claudin7 captured in glycolipid-enriched membrane microdomains promotes metastasis via associated transmembrane and cytosolic molecules. Oncotarget 7:30659–30677. https://doi.org/10.18632/oncotarget.8928
Todd MC, Petty HM, King JM, Piana Marshall BN, Sheller RA, Cuevas ME (2015) Overexpression and delocalization of claudin-3 protein in MCF-7 and MDA-MB-415 breast cancer cell lines. Oncol Lett 10:156–162. https://doi.org/10.3892/ol.2015.3160
Tokuhara Y, Morinishi T, Matsunaga T, Ohsaki H, Kushida Y, Haba R, Hirakawa E (2015) Claudin-1, but not claudin-4, exhibits differential expression patterns between well- to moderately-differentiated and poorly-differentiated gastric adenocarcinoma. Oncol Lett 10:93–98. https://doi.org/10.3892/ol.2015.3208
Tokuhara Y, Morinishi T, Matsunaga T et al (2018) Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues. Oncol Lett 15:99–108. https://doi.org/10.3892/ol.2017.7281
Tsukita S, Tanaka H, Tamura A (2019) The claudins: from tight junctions to biological systems. Trends Biochem Sci 44:141–152. https://doi.org/10.1016/j.tibs.2018.09.008
Van Itallie CM, Anderson JM (2006) Claudins and epithelial paracellular transport. Annu Rev Physiol 68:403–429. https://doi.org/10.1146/annurev.physiol.68.040104.131404
Van Itallie CM, Gambling TM, Carson JL, Anderson JM (2005) Palmitoylation of claudins is required for efficient tight-junction localization. J Cell Sci 118:1427–1436. https://doi.org/10.1242/jcs.01735
Van Itallie CM, Holmes J, Bridges A, Gookin JL, Coccaro MR, Proctor W, Colegio OR, Anderson JM (2008) The density of small tight junction pores varies among cell types and is increased by expression of claudin-2. J Cell Sci 121:298–305. https://doi.org/10.1242/jcs.021485
Van Itallie CM, Tietgens AJ, LoGrande K, Aponte A, Gucek M, Anderson JM (2012) Phosphorylation of claudin-2 on serine 208 promotes membrane retention and reduces trafficking to lysosomes. J Cell Sci 125:4902–4912. https://doi.org/10.1242/jcs.111237
Wang H, Yang X (2015) The expression patterns of tight junction protein claudin-1, -3, and -4 in human gastric neoplasms and adjacent non-neoplastic tissues. Int J Clin Exp Pathol 8:881–887
Wu J, Helftenbein G, Koslowski M, Sahin U, Tureci Ö (2006) Identification of new claudin family members by a novel PSI-BLAST based approach with enhanced specificity. Proteins Struct Funct Genet 65:808–815. https://doi.org/10.1002/prot.21218
Wu CJ, Mannan P, Lu M, Udey MC (2013) Epithelial cell adhesion molecule (EpCAM) regulates claudin dynamics and tight junctions. J Biol Chem 288:12253–12268. https://doi.org/10.1074/jbc.M113.457499
Yang P, Zhang M, Liu X, Pu H (2017) MicroRNA-421 promotes the proliferation and metastasis of gastric cancer cells by targeting claudin-11. Exp Ther Med 14:2625–2632. https://doi.org/10.3892/etm.2017.4798
Yu ASL (2015) Claudins and the kidney. J Am Soc Nephrol 26:11–19. https://doi.org/10.1681/ASN.2014030284
Zeisel MB, Dhawan P, Baumert TF (2019) Tight junction proteins in gastrointestinal and liver disease. Gut 68:547–561
Zhou S, Piao X, Wang C, Wang R, Song Z (2019) Identification of claudin-1, -3, -7 and -8 as prognostic markers in human laryngeal carcinoma. Mol Med Rep 20:393–400. https://doi.org/10.3892/mmr.2019.10265
Zhu JL, Gao P, Wang ZN, Song YX, Li AL, Xu YY, Wang MX, Xu HM (2013) Clinicopathological significance of claudin-4 in gastric carcinoma. World J Surg Oncol 11:150. https://doi.org/10.1186/1477-7819-11-150
Zhu L, Han J, Li L, Wang Y, Li Y, Zhang S (2019) Claudin family participates in the pathogenesis of inflammatory bowel diseases and colitis-associated colorectal cancer. Front Immunol. https://doi.org/10.3389/fimmu.2019.01441
Zwanziger D, Badziong J, Ting S, Moeller LC, Schmid KW, Siebolts U, Wickenhauser C, Dralle H, Fuehrer D (2015) The impact of claudin-1 on follicular thyroid carcinoma aggressiveness. Endocr Relat Cancer 22:819–830. https://doi.org/10.1530/ERC-14-0502
Acknowledgements
The work of Alla V Kuznetsova was conducted under the IDB RAS Government basic research program in 2021 No. 0088-2021-0017.
Funding
No special funding was received by the authors of this review.
Author information
Authors and Affiliations
Contributions
The first draft of the manuscript was written by OPP and all authors commented on previous versions of the manuscript, and AVK prepared the figure. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Ethics approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
The authors give their consent to publish this review article.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Popova, O.P., Kuznetsova, A.V., Bogomazova, S.Y. et al. Claudins as biomarkers of differential diagnosis and prognosis of tumors. J Cancer Res Clin Oncol 147, 2803–2817 (2021). https://doi.org/10.1007/s00432-021-03725-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-021-03725-0